1. ADA/EASD Position Statement: Approach to Hyperglycemia Management

2. ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

3. SGLT2 Inhibitors: Weight Reduction in Randomized Trials as Add-On to Metformin

4. SGLT2 Inhibitors: Glycemic Control Comparison as Add-On to Metformin

5. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

6. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality and HF Hospitalization

7. AEs in Pooled, Placebo-Controlled Studies of Dapagliflozin

8. Abbreviations